These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 19493247)

  • 21. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
    Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
    Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrice-daily biphasic insulin aspart 30 may be another therapeutic option for Chinese patients with type 2 diabetes inadequately controlled with oral antidiabetic agents.
    Yang WY; Ji QH; Zhu DL; Yang JK; Chen LL; Liu ZM; Yu DM; Yan L
    Chin Med J (Engl); 2009 Jul; 122(14):1704-8. PubMed ID: 19719975
    [No Abstract]   [Full Text] [Related]  

  • 23. Do diabetes drugs modify the risk of pancreatic cancer?
    Yang YX
    Gastroenterology; 2009 Aug; 137(2):412-5. PubMed ID: 19563838
    [No Abstract]   [Full Text] [Related]  

  • 24. Assessment of genomic instability in normal and diabetic rats treated with metformin.
    Attia SM; Helal GK; Alhaider AA
    Chem Biol Interact; 2009 Jul; 180(2):296-304. PubMed ID: 19497428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Editorial: cystic fibrosis.
    Gottlieb PA
    Curr Opin Endocrinol Diabetes Obes; 2010 Aug; 17(4):313. PubMed ID: 20588113
    [No Abstract]   [Full Text] [Related]  

  • 26. Metformin dispersible tablets: line extension. A welcome formulation of an essential drug.
    Prescrire Int; 2008 Aug; 17(96):138. PubMed ID: 19480093
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients.
    Kiyici S; Ersoy C; Kaderli A; Fazlioglu M; Budak F; Duran C; Gul OO; Sigirli D; Baran I; Tuncel E; Erturk E; Imamoglu S
    Diabetes Res Clin Pract; 2009 Oct; 86(1):44-50. PubMed ID: 19674806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Natural evolution, prediction, and prevention of type 1 diabetes in youth.
    Taplin CE; Barker JM
    Endocr Res; 2008; 33(1-2):17-33. PubMed ID: 19156572
    [No Abstract]   [Full Text] [Related]  

  • 30. [Pharmacological sheet. Vildagliptin, oral administration (GALVUS)].
    J Pharm Belg; 2009 Jun; (2):64-6. PubMed ID: 19739530
    [No Abstract]   [Full Text] [Related]  

  • 31. Therapies for type 2 diabetes and coronary artery disease.
    DeVries JH
    N Engl J Med; 2009 Oct; 361(14):1408-9; author reply 1409-10. PubMed ID: 19802918
    [No Abstract]   [Full Text] [Related]  

  • 32. Prevention and screening for type 2 diabetes in youth.
    Zeitler P; Pinhas-Hamiel O
    Endocr Res; 2008; 33(1-2):73-91. PubMed ID: 19156575
    [No Abstract]   [Full Text] [Related]  

  • 33. [Oral antidiabetic agents for the general practitioner].
    Siegmund T
    MMW Fortschr Med; 2009 Apr; 151(14):86, 88-91; quiz 92. PubMed ID: 19504847
    [No Abstract]   [Full Text] [Related]  

  • 34. Establishing pragmatic estimated glomerular filtration rate thresholds to guide metformin prescribing: careful assessment of risks and benefits is required.
    George JT; McKay GA
    Diabet Med; 2008 May; 25(5):636-7. PubMed ID: 18346163
    [No Abstract]   [Full Text] [Related]  

  • 35. [A clinical case of lactic acidosis development in a diabetic patient taking metformin].
    Cezur M; Celmen N; Cetinbas R; Badalov P; Erdemli O
    Anesteziol Reanimatol; 2009; (2):74-6. PubMed ID: 19514447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma concentration of pioglitazone in patients with type 2 diabetes on hemodialysis.
    Abe M; Kikuchi F; Okada K; Matsumoto K
    Ther Apher Dial; 2009 Jun; 13(3):238-9. PubMed ID: 19527473
    [No Abstract]   [Full Text] [Related]  

  • 37. Is it time to test metformin in breast cancer prevention trials? A reply to the authors.
    Barba M; Muti P
    Cancer Epidemiol Biomarkers Prev; 2009 Sep; 18(9):2565; author reply 2565. PubMed ID: 19745224
    [No Abstract]   [Full Text] [Related]  

  • 38. Self-monitoring of blood glucose: a test for patients or health-care professionals?
    Bhatnagar D
    Ann Clin Biochem; 2009 Jul; 46(Pt 4):271-2. PubMed ID: 19654101
    [No Abstract]   [Full Text] [Related]  

  • 39. Algorithm: management of diabetes mellitus: dietary and drug therapy.
    Shill J; Bethel MA; Feinglos MN
    Postgrad Med; 2009 Jul; 121(4):170-1. PubMed ID: 19641284
    [No Abstract]   [Full Text] [Related]  

  • 40. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
    Hermansen K; Dornhorst A; Sreenan S
    Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.